Government-Owned Inventions; Availability for Licensing, 34021-34022 [E7-11826]
Download as PDF
<![CDATA[
Federal Register / Vol. 72, No. 118 / Wednesday, June 20, 2007 / Notices
rwilkins on PROD1PC63 with NOTICES
cells in comparison to normal ovarian
epithelial cells. A better knowledge of
the mechanisms underlying ovarian
tumorigenesis will likely result in the
development of novel approaches for
the diagnosis and therapy of this deadly
disease.
Applications: Method to diagnose
ovarian cancer; Methods to treat
patients with compositions that inhibit
ovarian biomarkers such as siRNA.
Market: Ovarian cancer is the fourth
most common form of cancer in the
U.S.; Ovarian cancer is three times more
lethal than breast cancer; 22,430 new
cases of ovarian cancer expected in
2007; 15,280 ovarian cancer deaths in
the U.S. in 2007.
Development Status: The technology
is currently in the pre-clinical stage of
development.
Inventors: Patrice J. Morin et al. (NIA).
Related Publications:
1. KJ Hewitt, R Agarwal, PJ Morin.
The claudin gene family: expression in
normal and neoplastic tissues. BMC
Cancer. 2006 Jul 12;6:186.
2. PJ Morin. Claudin proteins in
human cancer: promising new targets
for diagnosis and therapy. Cancer Res.
2005 Nov 1;65(21):9603–9606.
3. R Agarwal, T D’Souza, PJ Morin.
Claudin–3 and claudin–4 expression in
ovarian epithelial cells enhances
invasion and is associated with
increased matrix metalloproteinase–2
activity. Cancer Res. 2005 Aug
15;65(16):7378–7385.
4. CD Hough, CA Sherman-Baust, ES
Pizer, PJ Morin. Use of SAGE to study
gene expression in ovarian cancer.
American Association for Cancer
Research, 9th Annual Meeting, April
10–14, 1999, Philadelphia,
Pennsylvania.
Patent Status: U.S. Provisional
Application No. 60/194,336 filed 03 Apr
2000 (HHS Reference No. E–138–2000/
0–US–01); PCT Patent Application No.
PCT/US2001/10947 filed 03 Apr 2001,
which published as WO 01/75177 on 11
Oct 2001 (HHS Reference No. E–138–
2000/0–PCT–02); U.S. Patent
Application No. 10/257,021 filed 03 Oct
2002 (HHS Reference No. E–138–2000/
0–US–03)
Licensing Status: Available for
exclusive or non-exclusive licensing.
Licensing Contact: Jennifer Wong;
301/435–4633; wongje@mail.nih.gov.
Dated: June 8, 2007.
Steven M. Ferguson,
Director, Division of Technology Development
and Transfer,Office of Technology
Transfer,National Institutes of Health.
[FR Doc. E7–11825 Filed 6–19–07; 8:45 am]
BILLING CODE 4140–01–P
VerDate Aug<31>2005
18:25 Jun 19, 2007
Jkt 211001
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
National Institutes of Health,
Public Health Service, HHS.
ACTION: Notice.
AGENCY:
SUMMARY: The inventions listed below
are owned by an agency of the U.S.
Government and are available for
licensing in the U.S. in accordance with
35 U.S.C. 207 to achieve expeditious
commercialization of results of
federally-funded research and
development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing.
ADDRESSES: Licensing information and
copies of the U.S. patent applications
listed below may be obtained by writing
to the indicated licensing contact at the
Office of Technology Transfer, National
Institutes of Health, 6011 Executive
Boulevard, Suite 325, Rockville,
Maryland 20852–3804; telephone: 301/
496–7057; fax: 301/402–0220. A signed
Confidential Disclosure Agreement will
be required to receive copies of the
patent applications.
Construction of Recombinant
Baculoviruses Carrying the Gene
Encoding the Major Capsid Protein,
VP1, From Calicivirus Strains
(Including Norovirus Strains Toronto,
Hawaii, Desert Shield, Snow Mountain,
and MD145–12)
Description of Technology: The
noroviruses (known as ‘‘Norwalk-like
viruses’’) are associated with an
estimated 23,000,000 cases of acute
gastroenteritis in the United States each
year. Norovirus illness often occurs in
outbreaks, affecting large numbers of
individuals, illustrated recently by wellpublicized reports of gastroenteritis
outbreaks on several recreational cruise
ships and in settings such as hospitals
and schools. Norovirus disease is clearly
important in terms of medical costs and
missed workdays, and accumulating
data support its emerging recognition as
important agents of diarrhea-related
morbidity.
Because the noroviruses cannot be
propagated by any means in the
laboratory, an important strategy in their
study is the development of molecular
biology-based tools. This invention
reports the development of recombinant
baculoviruses carrying the capsid gene
from several caliciviruses associated
PO 00000
Frm 00055
Fmt 4703
Sfmt 4703
34021
with human disease. Growth of these
baculovirus recombinants in insect cells
results in the expression of virus-like
particles (VLPs) that are antigenically
indistinguishable from the native
calicivirus particle. These VLPs can be
purified in large quantities for use as
diagnostic reagents and potential
vaccine candidates.
Inventors: Kim Y. Green, Judy F. Lew,
Adriene D. King, Stanislav V.
Sosnovtsev, Gael M. Belliot (NIAID).
Publication: An example of the
application of these materials is further
described in KY Green et al., ‘‘A
predominant role for Norwalk-like
viruses as agents of epidemic
gastroenteritis in Maryland nursing
homes for the elderly,’’ J. Infect. Dis.
2002 Jan. 15;185(2):133–146.
Patent Status: HHS Reference No. E–
198–2003/0—Research Material.
Licensing Status: The materials
embodied in this invention are available
nonexclusively through a biological
materials license.
Licensing Contact: Peter A. Soukas,
J.D.; 301/435–4646;
soukasp@mail.nih.gov
Collaborative Research Opportunity:
The Laboratory of Infectious Diseases,
NIAID, NIH, is seeking statements of
capability or interest from parties
interested in collaborative research to
further develop, evaluate, or
commercialize norovirus VLP antigens.
Please contact Kim Y. Green at
kgreen@niaid.nih.gov for more
information.
Full-Length cDNA Clone Representing
the Consensus Sequence of the RNA
Genome of a Human Norovirus (strain
MD145–12) That Encodes Biologically
Active Proteins
Description of Technology: The
invention provides for a full-length
cloned cDNA copy of the RNA genome
of a predominant norovirus strain
(Genogroup II.4) designated MD145–12
that was associated with human
gastrointestinal illness. The noroviruses,
which were formerly known as
‘‘Norwalk-like’’ viruses are estimated to
cause 23 million cases of acute
gastroenteritis in the USA each year.
The virus has been designated into
category B of the CDC biodefenserelated priority pathogens because it can
be used as an agent of bioterrorism. The
subject cDNA clone of the virus encodes
proteins of the MD145–12 strain that,
when expressed in vitro, exhibit
properties that would be expected from
those produced by the original
infectious virus. This cDNA clone is
presently the only source to obtain
norovirus proteins to facilitate studies
E:\FR\FM\20JNN1.SGM
20JNN1
34022
Federal Register / Vol. 72, No. 118 / Wednesday, June 20, 2007 / Notices
aimed at developing control strategies
such as vaccines and therapeutic drugs.
Inventors: Gael M. Belliot, Kim Y.
Green, Stanislav V. Sosnovtsev (NIAID)
Patent Status: HHS Reference No. E–
212–2003/0—Research Material
Licensing Status: The cDNA clone for
norovirus strain MD145–12 is available
for licensing via a biological material
license (BML).
Licensing Contact: Peter A. Soukas,
J.D.; 301/435–4646;
soukasp@mail.nih.gov.
Collaborative Research Opportunity:
The Laboratory of Infectious Diseases,
NIAID, NIH, is seeking statements of
capability or interest from parties
interested in collaborative research to
further develop, evaluate, or
commercialize reagents derived from a
cDNA clone of the genome of a
predominant human norovirus strain,
Genogroup II.4. Please contact Kim Y.
Green at kgreen@niaid.nih.gov for more
information.
rwilkins on PROD1PC63 with NOTICES
Construction of an Infectious FullLength cDNA Clone of the Porcine
Enteric Calicivirus RNA Genome
Description of Technology: Porcine
enteric calicivirus (PEC) is a member of
the genus Sapovirus in the family
Caliciviridae. This virus causes
diarrheal illness in pigs. In addition,
PEC serves as an important model for
the study of enteric caliciviruses that
cause diarrhea and that cannot be grown
in cell culture (including the
noroviruses represented by Norwalk
virus and the sapoviruses represented
by Sapporo virus). The development of
an infectious cDNA clone is important
because it enables the use of ‘‘reverse
genetics’’ to engineer mutations of
interest into the genome of PEC and to
study their effects. In addition, it allows
the introduction of foreign coding
sequences into the genome of PEC that
could be useful for vaccine development
in swine and possibly humans. This
discovery has both basic research
applications such as mapping mutations
involved in tissue culture adaptation,
tissue tropism, and virulence as well as
practical applications such as providing
a genetic backbone for the development
of chimeric vaccine viruses.
Inventors: Kyeong-Ok Chang (NIAID),
Stanislav V. Sosnovtsev (NIAID), Gael
M. Belliot (NIAID), Kim Y. Green
(NIAID), et al.
Publication: The materials are further
described in KO Chang et al., ‘‘Cellculture propagation of porcine enteric
calicivirus mediated by intestinal
contents is dependent on the cyclic
AMP signaling pathway,’’ Virology.
2002 Dec 20;304(2):302–310.
VerDate Aug<31>2005
18:25 Jun 19, 2007
Jkt 211001
Patent Status: HHS Reference No. E–
214–2003/0—Research Material.
Licensing Status: The materials
embodied in this invention are available
nonexclusively through a biological
materials license.
Licensing Contact: Peter A. Soukas,
J.D.; 301/435–4646;
soukasp@mail.nih.gov
Collaborative Research Opportunity:
The Laboratory of Infectious Diseases,
NIAID, NIH, is seeking statements of
capability or interest from parties
interested in collaborative research to
further develop, evaluate, or
commercialize reagents derived from an
infectious cDNA copy of the genome of
porcine enteric calicivirus. Please
contact Kim Y. Green at
kgreen@niaid.nih.gov for more
information.
Enzymatically-Active RNA-Dependent
RNA Polymerase From a Human
Norovirus (Calicivirus)
Description of Technology: The
noroviruses (formerly known as
‘‘Norwalk-like viruses’’) are associated
with gastroenteritis outbreaks, affecting
large numbers of individuals each year.
Emerging data are supporting their
increasing recognition as important
agents of diarrhea-related morbidity and
mortality. The frequency with which
noroviruses are associated with
gastroenteritis as ‘‘food and water-borne
pathogens’’ has led to the inclusion of
caliciviruses as Category B Bioterrorism
Agents/Diseases. Because the
noroviruses cannot be propagated by
any means in the laboratory, an
important strategy in their study is the
development of molecular biology-based
tools and replication systems. This
invention reports the isolation of the
first recombinant, enzymatically-active
proteinase and RNA dependent RNA
polymerase (RdRp) complex for a
human norovirus. This enzyme should
facilitate studies aimed at developing
therapeutic drugs for norovirus disease.
Inventors: Gael M. Belliot, Stanislav
V. Sosnovtsev, Kyeong-Ok Chang, Kim
Y. Green (NIAID).
Publication: The materials are further
described in L Wei et al., ‘‘Proteinasepolymerase precursor as the active form
of feline calicivirus RNA-dependent
RNA polymerase,’’ J. Virol. 2001
Feb;75(3):1211–1219.
Patent Status: HHS Reference No. E–
283–2003/0—Research Material.
Licensing Status: The materials
embodied in this invention are available
nonexclusively through a biological
materials license.
Licensing Contact: Peter A. Soukas,
J.D.; 301/435–4646;
soukasp@mail.nih.gov.
PO 00000
Frm 00056
Fmt 4703
Sfmt 4703
Collaborative Research Opportunity:
The Laboratory of Infectious Diseases,
NIAID, NIH, is seeking statements of
capability or interest from parties
interested in collaborative research to
further develop, evaluate, or
commercialize an active human
norovirus proteinase-polymerase
enzyme. Please contact Kim Y. Green at
kgreen@niaid.nih.gov for more
information.
Dated: June 8, 2007.
Steven M. Ferguson,
Director,Division of Technology Development
and Transfer,Office of Technology
Transfer,National Institutes of Health.
[FR Doc. E7–11826 Filed 6–19–07; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
National Institutes of Health,
Public Health Service, HHS.
ACTION: Notice.
AGENCY:
SUMMARY: The inventions listed below
are owned by an agency of the U.S.
Government and are available for
licensing in the U.S. in accordance with
35 U.S.C. 207 to achieve expeditious
commercialization of results of
federally-funded research and
development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing.
ADDRESSES: Licensing information and
copies of the U.S. patent applications
listed below may be obtained by writing
to the indicated licensing contact at the
Office of Technology Transfer, National
Institutes of Health, 6011 Executive
Boulevard, Suite 325, Rockville,
Maryland 20852–3804; telephone: 301/
496–7057; fax: 301/402–0220. A signed
Confidential Disclosure Agreement will
be required to receive copies of the
patent applications.
Methods for Prevention and Treatment
of Polyomavirus Infection or
Reactivation
Description of Technology: Available
for licensing and commercial
development are methods of using two
MAP kinase kinase (MEK) inhibitors,
PD98059 and U0126, in the prevention
and treatment of polyomavirus
infection. Decrease in viral protein
expression upon treatment with the
MEK inhibitors has been demonstrated
E:\FR\FM\20JNN1.SGM
20JNN1
]]>Agencies
[Federal Register Volume 72, Number 118 (Wednesday, June 20, 2007)]
[Notices]
[Pages 34021-34022]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E7-11826]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, Public Health Service, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The inventions listed below are owned by an agency of the U.S.
Government and are available for licensing in the U.S. in accordance
with 35 U.S.C. 207 to achieve expeditious commercialization of results
of federally-funded research and development. Foreign patent
applications are filed on selected inventions to extend market coverage
for companies and may also be available for licensing.
ADDRESSES: Licensing information and copies of the U.S. patent
applications listed below may be obtained by writing to the indicated
licensing contact at the Office of Technology Transfer, National
Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville,
Maryland 20852-3804; telephone: 301/496-7057; fax: 301/402-0220. A
signed Confidential Disclosure Agreement will be required to receive
copies of the patent applications.
Construction of Recombinant Baculoviruses Carrying the Gene Encoding
the Major Capsid Protein, VP1, From Calicivirus Strains (Including
Norovirus Strains Toronto, Hawaii, Desert Shield, Snow Mountain, and
MD145-12)
Description of Technology: The noroviruses (known as ``Norwalk-like
viruses'') are associated with an estimated 23,000,000 cases of acute
gastroenteritis in the United States each year. Norovirus illness often
occurs in outbreaks, affecting large numbers of individuals,
illustrated recently by well-publicized reports of gastroenteritis
outbreaks on several recreational cruise ships and in settings such as
hospitals and schools. Norovirus disease is clearly important in terms
of medical costs and missed workdays, and accumulating data support its
emerging recognition as important agents of diarrhea-related morbidity.
Because the noroviruses cannot be propagated by any means in the
laboratory, an important strategy in their study is the development of
molecular biology-based tools. This invention reports the development
of recombinant baculoviruses carrying the capsid gene from several
caliciviruses associated with human disease. Growth of these
baculovirus recombinants in insect cells results in the expression of
virus-like particles (VLPs) that are antigenically indistinguishable
from the native calicivirus particle. These VLPs can be purified in
large quantities for use as diagnostic reagents and potential vaccine
candidates.
Inventors: Kim Y. Green, Judy F. Lew, Adriene D. King, Stanislav V.
Sosnovtsev, Gael M. Belliot (NIAID).
Publication: An example of the application of these materials is
further described in KY Green et al., ``A predominant role for Norwalk-
like viruses as agents of epidemic gastroenteritis in Maryland nursing
homes for the elderly,'' J. Infect. Dis. 2002 Jan. 15;185(2):133-146.
Patent Status: HHS Reference No. E-198-2003/0--Research Material.
Licensing Status: The materials embodied in this invention are
available nonexclusively through a biological materials license.
Licensing Contact: Peter A. Soukas, J.D.; 301/435-4646;
soukasp@mail.nih.gov
Collaborative Research Opportunity: The Laboratory of Infectious
Diseases, NIAID, NIH, is seeking statements of capability or interest
from parties interested in collaborative research to further develop,
evaluate, or commercialize norovirus VLP antigens. Please contact Kim
Y. Green at kgreen@niaid.nih.gov for more information.
Full-Length cDNA Clone Representing the Consensus Sequence of the RNA
Genome of a Human Norovirus (strain MD145-12) That Encodes Biologically
Active Proteins
Description of Technology: The invention provides for a full-length
cloned cDNA copy of the RNA genome of a predominant norovirus strain
(Genogroup II.4) designated MD145-12 that was associated with human
gastrointestinal illness. The noroviruses, which were formerly known as
``Norwalk-like'' viruses are estimated to cause 23 million cases of
acute gastroenteritis in the USA each year. The virus has been
designated into category B of the CDC biodefense-related priority
pathogens because it can be used as an agent of bioterrorism. The
subject cDNA clone of the virus encodes proteins of the MD145-12 strain
that, when expressed in vitro, exhibit properties that would be
expected from those produced by the original infectious virus. This
cDNA clone is presently the only source to obtain norovirus proteins to
facilitate studies
[[Page 34022]]
aimed at developing control strategies such as vaccines and therapeutic
drugs.
Inventors: Gael M. Belliot, Kim Y. Green, Stanislav V. Sosnovtsev
(NIAID)
Patent Status: HHS Reference No. E-212-2003/0--Research Material
Licensing Status: The cDNA clone for norovirus strain MD145-12 is
available for licensing via a biological material license (BML).
Licensing Contact: Peter A. Soukas, J.D.; 301/435-4646;
soukasp@mail.nih.gov.
Collaborative Research Opportunity: The Laboratory of Infectious
Diseases, NIAID, NIH, is seeking statements of capability or interest
from parties interested in collaborative research to further develop,
evaluate, or commercialize reagents derived from a cDNA clone of the
genome of a predominant human norovirus strain, Genogroup II.4. Please
contact Kim Y. Green at kgreen@niaid.nih.gov for more information.
Construction of an Infectious Full-Length cDNA Clone of the Porcine
Enteric Calicivirus RNA Genome
Description of Technology: Porcine enteric calicivirus (PEC) is a
member of the genus Sapovirus in the family Caliciviridae. This virus
causes diarrheal illness in pigs. In addition, PEC serves as an
important model for the study of enteric caliciviruses that cause
diarrhea and that cannot be grown in cell culture (including the
noroviruses represented by Norwalk virus and the sapoviruses
represented by Sapporo virus). The development of an infectious cDNA
clone is important because it enables the use of ``reverse genetics''
to engineer mutations of interest into the genome of PEC and to study
their effects. In addition, it allows the introduction of foreign
coding sequences into the genome of PEC that could be useful for
vaccine development in swine and possibly humans. This discovery has
both basic research applications such as mapping mutations involved in
tissue culture adaptation, tissue tropism, and virulence as well as
practical applications such as providing a genetic backbone for the
development of chimeric vaccine viruses.
Inventors: Kyeong-Ok Chang (NIAID), Stanislav V. Sosnovtsev
(NIAID), Gael M. Belliot (NIAID), Kim Y. Green (NIAID), et al.
Publication: The materials are further described in KO Chang et
al., ``Cell-culture propagation of porcine enteric calicivirus mediated
by intestinal contents is dependent on the cyclic AMP signaling
pathway,'' Virology. 2002 Dec 20;304(2):302-310.
Patent Status: HHS Reference No. E-214-2003/0--Research Material.
Licensing Status: The materials embodied in this invention are
available nonexclusively through a biological materials license.
Licensing Contact: Peter A. Soukas, J.D.; 301/435-4646;
soukasp@mail.nih.gov
Collaborative Research Opportunity: The Laboratory of Infectious
Diseases, NIAID, NIH, is seeking statements of capability or interest
from parties interested in collaborative research to further develop,
evaluate, or commercialize reagents derived from an infectious cDNA
copy of the genome of porcine enteric calicivirus. Please contact Kim
Y. Green at kgreen@niaid.nih.gov for more information.
Enzymatically-Active RNA-Dependent RNA Polymerase From a Human
Norovirus (Calicivirus)
Description of Technology: The noroviruses (formerly known as
``Norwalk-like viruses'') are associated with gastroenteritis
outbreaks, affecting large numbers of individuals each year. Emerging
data are supporting their increasing recognition as important agents of
diarrhea-related morbidity and mortality. The frequency with which
noroviruses are associated with gastroenteritis as ``food and water-
borne pathogens'' has led to the inclusion of caliciviruses as Category
B Bioterrorism Agents/Diseases. Because the noroviruses cannot be
propagated by any means in the laboratory, an important strategy in
their study is the development of molecular biology-based tools and
replication systems. This invention reports the isolation of the first
recombinant, enzymatically-active proteinase and RNA dependent RNA
polymerase (RdRp) complex for a human norovirus. This enzyme should
facilitate studies aimed at developing therapeutic drugs for norovirus
disease.
Inventors: Gael M. Belliot, Stanislav V. Sosnovtsev, Kyeong-Ok
Chang, Kim Y. Green (NIAID).
Publication: The materials are further described in L Wei et al.,
``Proteinase-polymerase precursor as the active form of feline
calicivirus RNA-dependent RNA polymerase,'' J. Virol. 2001
Feb;75(3):1211-1219.
Patent Status: HHS Reference No. E-283-2003/0--Research Material.
Licensing Status: The materials embodied in this invention are
available nonexclusively through a biological materials license.
Licensing Contact: Peter A. Soukas, J.D.; 301/435-4646;
soukasp@mail.nih.gov.
Collaborative Research Opportunity: The Laboratory of Infectious
Diseases, NIAID, NIH, is seeking statements of capability or interest
from parties interested in collaborative research to further develop,
evaluate, or commercialize an active human norovirus proteinase-
polymerase enzyme. Please contact Kim Y. Green at kgreen@niaid.nih.gov
for more information.
Dated: June 8, 2007.
Steven M. Ferguson,
Director,Division of Technology Development and Transfer,Office of
Technology Transfer,National Institutes of Health.
[FR Doc. E7-11826 Filed 6-19-07; 8:45 am]
BILLING CODE 4140-01-P
